Asthma severity in four countries of Latin America

BMC Pulmonary Medicine

Table 4 Self-reported medication used by severe asthma status in Argentina, Chile, Colombia, and Mexico, 2013–2015

	Severe asthma		Non-severe asthma		p-value	Overall
	N	(%)^a	N	(%)	p-value	N	(%)
SAMA	34	18.5	35	8.5	< 0.001	69	11.6
Tiotropium	34	18.5	4	1.0	< 0.001	38	6.4
Antihistamines	21	11.4	22	5.4	0.009	43	7.2
Anti-immunoglobulin E agents	15	8.2	0	–	< 0.001	15	2.5
ICS	183	99.5	361	88.0	< 0.001	544	91.6
High doses	162	88.0	15	3.7		177	29.8
Not high doses	21	11.4	346	84.4		367	61.8
LABA	173	94.0	248	60.5	< 0.001	421	70.9
Leukotriene antagonists	53	28.8	39	9.5	< 0.001	92	15.5
SABA	120	65.2	241	58.8	0.137	361	60.8
Systemic corticosteroids	20	10.9	0	–	< 0.001	20	3.4
Xanthine and adrenergics	10	5.4	6	1.5	0.006	16	2.7
Other asthma medications	0	–	1	0.2	1.000	1	0.2

SAMA short-acting muscarinic antagonist, ICS inhaled corticosteroids, LABA long-acting beta2-agonist, SABA short-acting beta2-agonist
^aThe values correspond to the percentage of each drug used and they may be overlapped

ISSN: 1471-2466